Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House Oversight Drug Pricing Hearings Will Begin With Expert, Patient Witnesses

Executive Summary

Manufacturers will avoid direct interrogation in first round, but Oversight Committee also seeking information from sponsors on reasons behind price increases. In US Senate, Susan Collins writes to HHS Secretary Alex Azar urging the department to move ahead with rebate reform.

You may also be interested in...



Why Is Congress Targeting These Six Medicines In Drug Price Hearing?

Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.

Six Pharma CEOs To Testify In House as Democrats, Trump Compete For Attention On Drug Pricing

While neither party is likely to make any big policy changes this year, the action from both sides of the aisle indicates politicians still see going after pharma as a winning issue with voters even as polls show voters are focused elsewhere. 

Congress Puts Focus Back On Drug Pricing With AbbVie Subpoena

House Oversight Committee Chair says AbbVie has failed to comply with requests for documents in committee's investigation of the drug pricing of 12 pharma companies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134361

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel